TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis.

Yuqin Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.